Quarter-Century PET/Computed Tomography Transformation of Oncology: Hepatobiliary and Pancreatic Cancer

Asha Kandathil; Rathan Subramaniam

doi:10.1016/j.cpet.2023.12.003

Quarter-Century PET/Computed Tomography Transformation of Oncology: Hepatobiliary and Pancreatic Cancer

PET Clin. 2024 Apr;19(2):163-175. doi: 10.1016/j.cpet.2023.12.003. Epub 2024 Jan 11.

Authors

Asha Kandathil¹, Rathan Subramaniam²

Affiliations

¹ Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX, USA. Electronic address: [email protected].
² Faculty of Medicine, Nursing, Midwifery and Health Sciences, University of Notre Dame Australia, Sydney, Australia; Department of Radiology, Duke University, Durham, NC, USA; Department of Medicine, University of Otago Medical School, Dunedin, New Zealand.

PMID: 38212214
DOI: 10.1016/j.cpet.2023.12.003

Abstract

[18F] Fluorodeoxyglucose (¹⁸F-FDG) PET/CT can improve the staging accuracy and clinical management of patients with hepatobiliary and pancreatic cancers, by detection of unsuspected metastases. ¹⁸F-FDG PET/CT metabolic parameters are valuable in predicting treatment response and survival. Metabolic response on ¹⁸F-FDG PET/CT can predict preoperative pathologic response to neoadjuvant therapy in patients with pancreatic cancer and determine prognosis. Several novel non-FDG tracers, such as ⁶⁸Ga prostate-specific membrane antigen (PSMA) and ⁶⁸Ga-fibroblast activation protein inhibitor (FAPI) PET/CT, show promise for imaging hepatobiliary and pancreatic cancers with potential for radioligand therapy.

Keywords: Cholangiocarcinoma; FDG PET/CT; Gall bladder carcinoma; Hepatocellular carcinoma; Pancreatic carcinoma.

Published by Elsevier Inc.

Publication types

Review

MeSH terms

Fluorodeoxyglucose F18
Gallium Radioisotopes
Humans
Male
Pancreatic Neoplasms* / diagnostic imaging
Positron Emission Tomography Computed Tomography*
Tomography, X-Ray Computed

Substances

Fluorodeoxyglucose F18
Gallium Radioisotopes